AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Neurogene Inc.
Video analysis: NGNE
All videosNo video analysis for this stock yet. Request one from our team.
News: NGNE
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
Bank of New York Mellon Corp acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 28,741 shares of the company's stock, valued at approximately $904,000. Bank of
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, September 15 at 1:00 p.m. ET A live webcast of the fireside chat will be accessible from.
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company's common stock to two new employees (the “Inducement Grants”) on September 1, 2026 (the “Grant Date”). The Indu.
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
BlackRock Inc. acquired a new position in shares of Neurogene Inc. (NASDAQ: NGNE) in the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,057,983 shares of the company's stock, valued at approximately $33,274,000. BlackRock Inc. owned about 6.70% of Neurogene at the end of the most
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2026 financial results and highlighted recent corporate updates. “The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term Phase 1/2 data showing durable, multidomain developmental gains that have not be.
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company's common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Induce.
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company's common stock to six new employees (the “Inducement Grants”) on July 6, 2026 (the “Grant Date”). The Inducemen.
Similar companies
-
Lineage Cell Therapeutics, Inc.
LCTX
·
New York Stock Exchange Arca
Compare
-
Ocugen, Inc.
OCGN
·
NASDAQ
Compare
-
Fulcrum Therapeutics, Inc.
FULC
·
NASDAQ
Compare
-
Autolus Therapeutics plc
AUTL
·
NASDAQ
Compare
-
ADC Therapeutics S.A.
ADCT
·
New York Stock Exchange
Compare
-
Benitec Biopharma Inc.
BNTC
·
NASDAQ
Compare